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Ataxia-telangiectasia (A-T) patients occasionally
develop diabetes mellitus. However, only limited
attempts have been made to gain insight into the
molecular mechanism of diabetes mellitus develop-
ment in A-T patients. We found that Atm/ mice
were insulin resistant and possessed less subcu-
taneous adipose tissue as well as a lower level of
serum adiponectin than Atm+/+ mice. Furthermore,
in vitro studies revealed impaired adipocyte differen-
tiation in Atm/ cells caused by the lack of induction
of C/EBPa and PPARg, crucial transcription factors
involved in adipocyte differentiation. Interestingly,
ATM was activated by stimuli that induced differenti-
ation, and the binding of ATM to C/EBPb and p300
was involved in the transcriptional regulation of
C/EBPa and adipocyte differentiation. Thus, our
study sheds light on the poorly understood role of
ATM in the pathogenesis of glucose intolerance in
A-T patients and provides insight into the role of
ATM in glucose metabolism.
INTRODUCTION
Ataxia-telangiectasia (A-T) is often accompanied by glucose
intolerance and insulin resistance (Bar et al., 1978; Blevins andCeGebhart, 1996; McFarlin et al., 1972; Morio et al., 2009; Schalch
et al., 1970), and our previous study revealed that 17% of A-T
patients developed type 2 diabetes mellitus (Morio et al.,
2009). A-T patients also exhibit poor weight gain, a progressive
decrease in their BMI, and progressive dystrophy (Schubert
et al., 2005). In addition to A-T patients, A-T carriers, who
comprise an estimated 0.05%–0.1% of the normal population,
suffer an increased risk of ischemic heart disease (Su and
Swift, 2000) and diabetes (Morrell et al., 1986). As in A-T
patients, glucose intolerance has been reported in Atm/,
Atm+/ApoE/, and Atm/ApoE/ mice (Miles et al., 2007;
Schneider et al., 2006); the Atm+/ApoE/mousemodel gener-
ates a state of insulin resistance similar to that observed in type 2
diabetes. In addition, Miles et al. reported impaired insulin secre-
tion in agedAtm/mice (Miles et al., 2007). However, themech-
anism by which an ATM deficiency affects the development of
type 2 diabetes remains unknown.
ATM, the gene responsible for A-T, plays a central role in
the DNA damage response. Previous reports have suggested
that ATM is activated in response to insulin stimulation and
phosphorylates the Cap-dependent translation inhibitor 4E-
BP1 (Yang and Kastan, 2000). A recent large-scale proteomic
ATM substrate analysis identified several proteins involved
in the insulin-signaling pathway, such as AKT and FOXO1
(Matsuoka et al., 2007). Together, these observations strongly
support the hypothesis that ATM is involved in the insulin-
signaling pathway and modulates glucose homeostasis.
Insulin resistance is a frequent complication of obesity;
however, lipoatrophic diabetes is paradoxical because it isll Reports 10, 957–967, February 17, 2015 ª2015 The Authors 957
Figure 1. Adipose Tissue Distribution in Atm+/+ and Atm/ Mice
(A) Intrascapular fat tissue and (B) hematoxylin-eosin staining of the back skin of Atm+/+ and Atm/mice. The lower graphs indicate the amount of fat tissue. The
Atm/ mice were relatively smaller than the Atm+/+ mice. The relative amount of fat tissue per body weight is also shown. The mean values from three inde-
pendent experiments are shown (A and B).characterized by insulin resistance despite the existence of a
low-fat mass. Insulin resistance in lipoatrophic diabetes may be
due to the defective development of adipose tissue and the sub-
sequently impaired secretion of adipokines, such as adiponectin
or leptin (Rosen and Spiegelman, 2006). Adipocytes secrete
several adipokines, such as adiponectin, leptin, visfatin, and
omentin, which increase insulin sensitivity. Conversely, adipo-
kines that are secreted by hypertrophic adipocytes, such as re-
sistin and tumor necrosis factor a (TNF-a), act to decrease
insulin sensitivity. Alterations in adiposity have profound implica-
tions for glucose homeostasis, and an appropriate balance of
adiposity is required to maintain adequate glucose homeostasis.
The central engine for adipose differentiation involves CCAAT/
enhancer-binding protein a (C/EBPa) and peroxisome prolifera-
tor activated receptor g (PPARg). When this receptor is activated
by an agonistic ligand in fibroblasts, a full program of differenti-
ation is stimulated, including morphological changes, lipid accu-
mulation, and the expression of almost all genes characteristic of
fat cells. Multiple C/EBPs, such as C/EBPb and C/EBPd, are
expressed during the early stages of differentiation; subse-
quently, C/EBPa and PPARg expression is driven by C/EBPb
and C/EBPd. C/EBPs and PPARg also directly activate many
genes in terminally differentiated adipocytes (Rosen and Spie-
gelman, 2000).
To understand the molecular mechanism of diabetes develop-
ment in A-T patients, we investigated the adipose tissue distribu-
tion and degree of adipocyte maturation in Atm knockout mice.
Examination of mouse embryonic fibroblasts (MEFs) derived
from wild-type (Atm+/+) or Atm knockout (Atm/) mice revealed
that adipocytic differentiation did not occur in Atm/MEFs. The
impaired adipocyte differentiation observed inAtm/MEFswas
due to the defective ATM-dependent induction of C/EBPa and
PPARg expression. These observations strongly support the hy-958 Cell Reports 10, 957–967, February 17, 2015 ª2015 The Authorspothesis that glucose intolerance and insulin resistance in A-T
patients are due to attenuated adipocyte functioning.
RESULTS
Atm Knockout Mice Exhibited Glucose Intolerance,
Insulin Resistance, and Abnormal Adipose Distribution
As previously suggested, Atm/ mice were glucose intolerant,
and their condition mimicked type 2 diabetes mellitus (Figures
S1A–S1G). Interestingly, Atm+/ mice exhibited neither glucose
intolerance nor insulin resistance, although Atm+/ male mice
fed a high-fat diet exhibited glucose intolerance and insulin resis-
tance (Figures S1H and S1I). A-T patients have lean figures and a
reduced level of subcutaneous fat tissue. In contrast, an
increased amount of visceral fat tissue was reported in
Atm+/ApoE/mice (Schneider et al., 2006). Therefore, the ad-
ipose distribution inAtm/mice was re-evaluated.We detected
a decreased amount of intrascapular and subcutaneous fat tis-
sue in Atm/mice compared to their wild-type littermates (Fig-
ures 1A and 1B). Conversely, Atm/mice showed an increased
level of visceral fat tissue, as previously reported, similarly to hu-
man metabolic syndrome, which is also associated with a high
accumulation of visceral fat (Matsuzawa, 2006) (Figures S1J–
S1L). In addition, a reduced serum level of adiponectin was pre-
viously observed in Atm+/ApoE/ mice (Schneider et al.,
2006). As expected, Atm/ mice also showed reduced serum
adiponectin and leptin levels, whereas Atm+/ mice exhibited
levels intermediate between those of Atm/ and Atm+/+ mice
(Figures S1M and S1N). The fat redistribution, increase in
visceral fat tissue, and reduction in subcutaneous fat tissue
observed in Atm/ mice may be explained by their increased
appetite, which is due to their reduced level of leptin
(Figure S1O).
Figure 2. ATM-Null Cells Are Defective in Adipocyte Differentiation
(A) Oil red O staining of in-vitro-differentiated Atm+/+ and Atm/ MEFs. The right panel shows magnified images of parts of the left panel.
(B) The intracellular triglyceride concentrations of Atm+/+ and Atm/ MEFs are shown.
(C) In-vitro-differentiated Atm+/+ and Atm/ MEFs were assayed for radiolabeled 2-deoxyglucose uptake in the presence of 5 mg/ml insulin.
The SEs are shown as error bars (*p < 0.05).ATM-Deficient Cells Were Defective in Adipocyte
Differentiation
The reduced amount of subcutaneous fat tissue and reduced
level of serum adiponectin in Atm knockout mice suggested a
defect in adipocyte functioning. To evaluate the function of adi-
pose tissue in Atm knockout mice, an in vitro adipocyte differen-
tiation model (Tanaka et al., 1997) was employed, using Atm/
and Atm+/+ MEFs. After the MEFs were stimulated to differen-
tiate into adipocytes, the Atm+/+ MEFs showed lipid accumula-
tions, as indicated by Oil red O staining, whereas the Atm/
MEFs failed to differentiate into adipocytes (Figure 2A). To eval-
uate the ability of the cells to differentiate into adipocytes, the
intracellular triglyceride levels of these cells after differentiation
stimulation were compared. Atm/ MEFs showed an approxi-
mately 85% triglyceride level compared with that of Atm+/+
MEFs (Figure 2B). Glucose uptake was evaluated in cells that
were induced to differentiate for 6 days, and the Atm/ MEFs
showed approximately 75% less glucose uptake compared to
Atm+/+ MEFs (Figure 2C). Adipocyte differentiation capacity us-
ing stromal vascular fractions (SVFs) from Atm+/+ and Atm/
mice was also examined. As observed in the MEFs, the Atm/
SVFs exhibited a defective adipocyte differentiation capacity
(Figure S2A).
Adipocyte differentiation experiments frequently utilize 3T3-L1
preadipocytes. To confirm the results obtained usingAtm/ and
Atm+/+MEFs and SVFs, adipocyte differentiation was also inves-
tigated in 3T3-L1 cells treated with the ATM inhibitors caffeine
and KU55933. As expected, treatment with caffeine and
KU55933 blocked adipocyte differentiation in 3T3-L1 cells (Fig-
ure S2B). To confirm that adipocytic differentiation was depen-
dent on ATM function, the genome ofAtm/MEFswas comple-
mented with wild-type or kinase-dead ATM cDNA via expression
vectors; onlywild-typeATM restored the in vitro ability of the cells
to differentiate into adipocytes (Figure S2C). ATM-deficient cells
accumulate reactive oxygen species (ROS) (Ito et al., 2004),
which may interfere with differentiation in vitro. To investigate
whether ROS interfered with adipocyte differentiation, Atm/CeMEFswere pretreatedwith theROS scavenger N-acetyl cysteine
(NAC), and differentiation was induced in the presence of NAC.
However, NAC treatment failed to rescue adipocyte differentia-
tion in Atm/ MEFs (Figure S2D). These experiments demon-
strated that ATM is required for proper adipocyte differentiation
and that ROS are not involved in this process.
ATM-Deficient Cells Showed Defective Induction of
Transcriptional Factors Required for Adipocyte
Differentiation
To clarify the molecular mechanism of attenuated adipocyte dif-
ferentiation inAtm/MEFs, several factors with possible roles in
adipocyte differentiation were investigated in Atm+/+ and Atm/
MEFs upon differentiation induction. C/EBPa and PPARg
expressionwasobserved4–6 days after the induction of differen-
tiation inAtm+/+MEFs, whereasAtm/MEFs completely lacked
C/EBPa and PPARg expression. In contrast, C/EBPb and
C/EBPd expression was induced normally upon the differentia-
tion of Atm/ MEFs (Figure 3A). A-T cells have been previously
reported to show decreased expression of the IGF1 receptor,
which is the primary mediator of the insulin-signaling pathway
(Peretz et al., 2001; Shahrabani-Gargir et al., 2004). However,
there was no significant difference in the levels of expression of
the IGF1 receptor of Atm+/+ and Atm/MEFs (Figure 3A). These
twoobservations suggested that signalingpathwaysupstreamof
C/EBPb and C/EBPd were regulated normally in Atm/ MEFs
during differentiation and that the impaired adipocyte differentia-
tion of Atm/ MEFs was caused by defective C/EBPa and
PPARg expression. Real-time qPCR and northern blot revealed
that the expression of C/EBPa and PPARgmRNA was dysregu-
lated at the transcriptional level (Figures 3B, 3C, and S2E).
KU55933 blocked adipocyte differentiation in 3T3-L1 cells (Fig-
ure S2B), which was accompanied by the aberrant induction of
C/EBPa expression (Figure S2F). Adipocyte differentiation via
wild-typeATMcomplementation ofAtm/MEFs restored the in-
duction of C/EBPa expression, whereas kinase-dead ATM
complementation failed to restore this process (Figure S2G).ll Reports 10, 957–967, February 17, 2015 ª2015 The Authors 959
Figure 3. C/EBPa and PPARg Expression
during the Adipocyte Differentiation Pro-
cess
(A) Western blotting analyses of in-vitro-differen-
tiated Atm+/+ and Atm/ MEFs.
(B and C) The levels of C/EBPa and PPARgmRNA
expression after differentiation were analyzed with
qRT-PCR. The mean values from three indepen-
dent experiments are shown in the bar graphs.
The SEs are shown as error bars (*p < 0.05).These results suggested that the impaired adipocyte differentia-
tion observed inAtm/ cells was caused by a defect in the ATM-
dependent transcriptional activation of C/EBPa and PPARg
expression upon differentiation stimulation.
Complementation of C/EBPa or PPARg Restored the
Adipocyte Differentiation Capacity of Atm/ Cells
C/EBPa and PPARg are necessary for the terminal differentiation
of adipocytes, and the aberrant expression of C/EBPa and
PPARg is thought to be the central cause of impaired adipocyte
differentiation in Atm/ MEFs. Thus, we tested whether defec-
tive differentiation would be rescued by the overexpression of
C/EBPa or PPARg in Atm/ MEFs. Atm/ MEFs were trans-
duced using retroviruses for the expression of HA-tagged
C/EBPa or FLAG-tagged PPARg2 and the internal ribosome en-
try sequence (IRES)-dependent expression of GFP, and then
GFP-positive cells were cultured under conditions that stimu-
lated differentiation. The overexpression of either HA-tagged
C/EBPa or FLAG-tagged PPARg2 restored the ability of Atm/
MEFs to differentiate into adipocytes (Figures S2H and S2J).
Furthermore, the overexpression of HA-tagged C/EBPa or
FLAG-tagged PPARg2 induced the endogenous expression of
PPARg or C/EBPa (Figures S2I and S2K).960 Cell Reports 10, 957–967, February 17, 2015 ª2015 The AuthorsATM-Deficient Cells Were Deficient
in Cell-Cycle Regulation after
Differentiation Stimulation
In addition to the major adipocyte tran-
scriptional differentiation inducers, such
as C/EBPa or PPARg, several factors
that participate in cell-cycle regulation
are involved in adipocyte differentiation
(Abella et al., 2005; Fajas et al., 2002).
Upon differentiation stimulation, the cells
that are arrested by contact inhibition re-
enter the cell cycle, in a process referred
to as clonal expansion (Tang et al.,
2003). After two to three rounds of prolif-
eration, the cell cycle is halted in these
cells, and they enter the process of ter-
minal differentiation (Rosen and Spiegel-
man, 2000). Thus, the cell-cycle kinetics
of Atm+/+ and Atm/ MEFs undergoing
differentiation was investigated. The re-
sults of a bromodeoxyuridine (BrdU)
pulse-labeling experiment revealed that
Atm+/+ and Atm/ MEFs re-entered
the cell cycle normally after differentiation stimulation, but the
cell cycle was not halted in Atm/ MEFs at 8 days after differ-
entiation stimulation (Figure S3A). Monitoring the RB phosphor-
ylation status using western blotting analysis showed lack of
RB dephosphorylation at the terminal stage of differentiation
in Atm/ MEFs (Figure S3B). The induction of cyclin A expres-
sion upon differentiation stimulation was also observed in
Atm+/+ and Atm/ MEFs; cyclin A expression declined at
6 days after differentiation stimulation in Atm+/+ MEFs, but its
expression persisted in Atm/ MEFs (Figure S3C). The expres-
sion of E2F4, which halts the adipogenic differentiation process
(Fajas et al., 2002), was gradually upregulated, reaching a
maximum level at 6 days after differentiation stimulation in
Atm+/+ MEFs. Interestingly, the level of expression of E2F4
was constitutively high in Atm/ MEFs (Figure S3C). These ob-
servations demonstrated that, although Atm/ MEFs could
re-enter the clonal expansion phase, they failed to show the
cell-cycle arrest necessary for the terminal differentiation pro-
cess. Interestingly, the overexpression of HA-tagged C/EBPa
induced cell-cycle arrest after the clonal expansion of Atm/
MEFs via RB dephosphorylation (Figures S3D and S3E), sug-
gesting that C/EBPa functions upstream of cell-cycle
regulators.
Figure 4. ATM Is Activated during Differentiation
(A) The ATM phosphorylation status after in vitro differentiation was determined by western blotting analysis of immunoprecipitates.
(B) ATM phosphorylation 1 day after in vitro differentiation and 3 hr after 5-Gy irradiation, as detected using immunofluorescence.
(C) CREB phosphorylation upon in vitro differentiation was analyzed using western blotting.ATM Was Activated by Stimuli that Induce
Differentiation
ATM is activated by DNA damage signals as well as insulin stim-
ulation (Yang and Kastan, 2000), and ATM activation can be
monitored according to the intermolecular autophosphorylation
of its serine-1981 (Bakkenist and Kastan, 2003). Therefore, the
autophosphorylation of ATM during adipogenesis was investi-
gated. During adipocyte differentiation, ATM was activated
(Figure 4A). Differentiation-stimulated cells showed a diffuse
phosphorylated ATMpattern in contrast to the irradiated positive
control cells, which showed diffuse and discrete foci of phos-
phorylated ATM (Figures 4B and S4A). This ATM activation
process was not associated with DNA double-strand breakage
(Figure S4B). ATM activation upon differentiation stimulation
also resulted in the phosphorylation of the ATM downstream
target CREB at serine-121 (Shi et al., 2004), which is required
for adipocyte differentiation (Zhang et al., 2004) (Figure 4C).
ATM Was Required for the Induction of C/EBPa
Transcription by C/EBPb
The above-described results strongly suggest that ATM activa-
tion contributes to adipogenesis via the regulation of C/EBPa
and/or PPARg transcription, although the expression of
C/EBPb and C/EBPd was induced normally in Atm/ MEFs.
C/EBPb and C/EBPd are involved in C/EBPa transcription
through binding to the C/EBP-binding sequence in the
C/EBPa promoter and acting as upstream transcription factors
for C/EBPa. Therefore, C/EBPb binding to the C/EBPa promoter
was investigated. Chromatin immunoprecipitation (ChIP) assays
revealed that C/EBPb bound equally to the C/EBPa promoter in
Atm+/+ and Atm/ MEFs upon differentiation stimulation (Fig-
ure 5A). However, the activity of the C/EBPa promoter, as deter-
mined using a luciferase assay, was completely abolished in
Atm/ MEFs (Figure 5B). Furthermore, this dysregulation of
C/EBPa transcription attenuated the histone H3 and H4 acety-
lation in the C/EBPa promoter region (Figure 5C). Together,
these experiments showed that C/EBPb bound to the C/EBPaCepromoter but could not transactivate the C/EBPa promoter in
the absence of ATM.
ATM Bound to C/EBPb and p300 Was Recruited to the
ATM-C/EBPb Complex
An electromobility shift assay (EMSA) revealed a protein com-
plex bound to the C/EBPa promoter in Atm+/+ and Atm/
MEFs. However, examination of nuclear extracts of Atm/
MEFs showed that the mobility of several protein complexes
that bind to the C/EBPa promoter was retarded in these cells
(Figure S5), suggesting that the composition or modification of
protein complexes that bind to the C/EBPa promoter were
different in Atm+/+ and Atm/ MEFs. The C/EBPb binding part-
ners in Atm+/+ and Atm/ MEFs were investigated using an
immunoprecipitation assay, which showed that ATM bound to
C/EBPb upon differentiation stimulation (Figure 6A). C/EBPb is
known to bind to CBP/p300, a phosphorylation target of ATM,
and modulate its transcriptional activity (Jang et al., 2010;
Schwartz et al., 2003; Wang et al., 2007), and the acetylation
of histone H3 and H4 near the C/EBPa promoter was attenuated
in Atm/ MEFs. Thus, we hypothesized that histone acetyl
transferase is recruited to the ATM-C/EBPb complex and acety-
lates histones near the C/EBPa promoter. Therefore, the associ-
ation of histone acetyl transferase with C/EBPbwas investigated
using an immunoprecipitation assay. Screening for several his-
tone acetyl transferases, including GCN5, p300, CBP, and
Tip60, demonstrated that ATM and C/EBPb bound to p300
upon differentiation and that the binding of ATM to C/EBPb
and p300 was augmented upon differentiation stimulation.
Furthermore, co-immunoprecipitation assays revealed that
ATM, C/EBPb, and p300 formed a ternary complex upon differ-
entiation stimulation, with C/EBPb-p300 binding being depen-
dent upon the presence of ATM (Figure 6A). C/EBPb threonine
188 (threonine 235 in humans) phosphorylation is required for
its transcriptional activation; upon differentiation stimulation,
Atm+/+ MEFs showed phosphorylation of C/EBPb at threonine
188, whereas this effect was absent in Atm/MEFs (Figure 6B).ll Reports 10, 957–967, February 17, 2015 ª2015 The Authors 961
Figure 5. C/EBPb Transcriptional Activity
Depends on ATM
(A) A ChIP assay using an anti-C/EBPb antibody
(H7) showed that C/EBPb bound to the C/EBPa
promoter sequence in Atm+/+ and Atm/ MEFs.
(B) C/EBPa promoter activation in Atm+/+ and
Atm/ MEFs before and 3 days after differentia-
tion stimulation, as determined using a luciferase
assay.
(C) Analyses of the histone H3 and H4 acetylation
status proximal to the C/EBPa promoter using a
ChIP assay. The mean values from three inde-
pendent experiments are shown.
The SEs are shown as error bars (*p < 0.05).It is known that C/EBPb threonine 188 is directly phosphorylated
by ERK, and it is also known that ATM/ cells exhibit defective
MAPK activation (Kim and Wong, 2009; Raman et al., 2007). To
link these two observations, we tested whether the activation of
the MAPK-signaling pathway was defective in Atm/ cells after
differentiation stimulation. As expected, Atm/MEFs exhibited
defective MEK1 and ERK activation (Figure S6). Thus, the defect
in C/EBPb phosphorylation inAtm/ cells may be due to the fail-
ure of MAPK-signaling pathway activation.
Restoration of Adipose Functioning in Atm/ Mice
Improved Their Glucose Intolerance
Based on our findings, agents such as the PPARg ligand thiazo-
lidione, which induces adipocyte differentiation, may be effective
candidates for treating glucose intolerance in A-T patients.
Indeed, rosiglitazone treatment restored adipocyte differentia-
tion in Atm/MEFs (Figures 7A and 7B), and pioglitazone treat-
ment ameliorated glucose intolerance in Atm/ mice (Figures
7C and 7D) and increased their serum adiponectin concentra-
tions (Figure 7E), suggesting a restoration of fat tissue func-
tioning. Metformin treatment also improved glucose intolerance
in these mice (Figures 7C and 7D). The increase in insulin sensi-
tivity with metformin treatment wasmilder than that with pioglita-
zone treatment; however, the results were not significantly
different. Furthermore, metformin treatment did not affect the
serum adiponectin concentration, suggesting that metformin
improved the glycemic response through a fat-tissue-indepen-
dent pathway (Figure 7E). Previously, surgical implantation of
normal fat tissue was reported to rescue insulin resistance in lip-
odystrophic mice (Gavrilova et al., 2000). Therefore, we surgi-
cally implanted fat tissue derived from wild-type and Atm
knockout littermates into Atm/ mice (Figures S7A and S7B),
and only wild-type fat transplantation successfully reversed the962 Cell Reports 10, 957–967, February 17, 2015 ª2015 The Authorsglucose intolerance and insulin resis-
tance of Atm/ mice and increased
their levels of serum adiponectin (Figures
7F–7H).
DISCUSSION
A-T patients often exhibit glucose intoler-
ance and insulin resistance and possess
less subcutaneous adipose tissue thanhealthy individuals. Glucose intolerance was reported not only
in A-T patients, but also in the Atm knockout mousemodel (Miles
et al., 2007; Schneider et al., 2006). We confirmed that Atm
knockout mice are insulin resistant and possess less subcutane-
ous adipose tissue, accompanied by a lower level of serum adi-
ponectin, than their wild-type littermates. Furthermore, in vitro
investigations usingMEFs revealed that adipocyte differentiation
was impaired in Atm/ cells, which was caused by the lack of
induction of C/EBPa and PPARg, crucial transcription factors
involved in adipocyte differentiation. These observations sug-
gest that the glucose intolerance and insulin resistance of A-T
patients are due to the improper functioning of their adipose tis-
sue due to the attenuation of adipocyte differentiation.
Recently, a link was established between the DNA damage
checkpoint pathway and cellular metabolism. Previous reports
have shown that the ATM-p53 pathway participates in glucose
metabolism (Armata et al., 2010;Minamino et al., 2009), although
the molecular mechanisms involved in this process remain un-
clear. Our findings demonstrate the importance of the DNA dam-
age checkpoint pathway in the regulation of cellular metabolism
and homeostasis in vivo. It is also clear that transcriptional regu-
lation by ATM plays an important role in cellular differentiation.
ATM is reportedly required for the retinoic-acid-induced differen-
tiation of SH-SY5Y neuroblastoma cells to neuronal-like cells.
Retinoic acid rapidly triggers the activity of ATM kinase, resulting
in the ATM-dependent phosphorylation of the transcription fac-
tor CREB (Fernandes et al., 2007). In the case of adipocyte differ-
entiation, ATM is also activated by extracellular signals. In our
model of adipocyte differentiation, C/EBPa transcription
required ternary complex formation by ATM, C/EBPb, and the
histone acetyl transferase p300, which was associated with
the phosphorylation of C/EBPb at threonine 235. The recruit-
ment of p300 to the C/EBPb complex activated the
Figure 6. ATM Forms a Ternary Complex
with C/EBPb and p300
(A) ATM bound to p300 and C/EBPb upon differ-
entiation (left). p300 bound to ATM and C/EBPb
upon differentiation (middle). C/EBPb bound to
ATM and p300 upon differentiation (right). Immu-
noprecipitation using the indicated antibodies was
performed before and after the differentiation of
Atm+/+ and Atm/ MEFs. The anti-C/EBPb (H7)
antibody immunoprecipitated only the active p34
LAP form of C/EBPb.
(B) C/EBPb was phosphorylated in an ATM-
dependent manner. C/EBPb was immunoprecipi-
tated from Atm+/+ and Atm/ MEF lysates and
detected using western blotting with an anti-
phospho-C/EBPb threonine 235 (threonine 188 in
mouse) antibody.C/EBPb-dependent transcription of C/EBPa through the modifi-
cation of histone acetylation. The phosphorylation of C/EBPb at
threonine 235, reportedly by ERK and GSK3, is required for its
transcriptional activity (Park et al., 2004). Moreover, ERK activa-
tion by DNA damage is dependent upon ATM (Tang et al., 2002).
It is possible that other components of the C/EBPb com-
plex(es) are targets of ATM phosphorylation and that this phos-
phorylation is a prerequisite for the formation of the complex(es).
In fact, C/EBPb and the C/EBPb-binding partners p300, CREB,
and FOXO1, as well as the negative regulator of adipocyte differ-
entiation Sp1 and the positive regulator of adipocyte differentia-
tion E2F1, carry ATM phosphorylation consensus residues and
are phosphorylated by ATM (Iwahori et al., 2008; Jang et al.,
2010; Lin et al., 2001). Therefore, the phosphorylation of tran-
scription factors and associated proteins by ATM, including
the C/EBPb-p300 complex, may play a central role in adipocytic
differentiation.
The DNA damage response pathway has been linked with the
state of cellular glucose metabolism (Armata et al., 2010; Mina-
mino et al., 2009) and fat metabolism (Wong et al., 2009).
Furthermore, components of the DNA break/repair machinery,
including DNA-PK, Ku70/80, PARP-1, and topoisomerase IIb,
as well as protein phosphatase 1, are recruited to the fatty acid
synthase promoter in mice immediately after feeding (Wong
et al., 2009). Transient DNA breaks were recently reported to
be required for estrogen-receptor-regulated transcription (Ju
et al., 2006), and ATM is hypothesized to be required for the
DNA-break-dependent transcriptional regulation of C/EBPa,
similar to the case for DNA-PK. Indeed, topoisomerase b is
phosphorylated in an ATM-dependent manner in response to
DNA damage (Bensimon et al., 2010).
The amount of intrascapular and subcutaneous fat tissue in
Atm/ mice was less than that of their wild-type littermates.
Conversely, Atm/ mice showed an increased amount of
visceral fat tissue, as previously reported (Schneider et al.,
2006), comparable to that observed in lipodystrophy, HIV infec-
tion, or human metabolic syndrome, conditions that are associ-
ated with a high accumulation of visceral fat (Matsuzawa, 2006;
Safrin and Grunfeld, 1999). Although it is not known why subcu-
taneous fat tissue is preferentially affected in Atm/ mice, we
propose several hypotheses to explain this phenomenon. First,Cethe increased appetite ofAtm/mice due to their reduced leptin
level may preferentially induce fat accumulation in the visceral fat
tissue (Figure S1O). Second, the caveolin-1 knockout mouse is
one of the best-characterized lipodystrophic mouse models.
Although this phenotype is observed late in life, all types of fat tis-
sues in this mouse exhibit the lipodystrophic phenotype. As
young animals, the only types of adipose tissue that are affected
are the female mammary and subcutaneous white adipose tis-
sue (Razani et al., 2002). As previously reported for caveolin-1
knockout mice, subcutaneous fat tissue of Atm/ mice may
be much more sensitive than other fat tissues to defects in the
adipocyte differentiation machinery. Third, the association be-
tween age and lipodystrophy may be mediated by the increased
number of deletions in the mitochondrial (mt) DNA that naturally
occur with aging (Walker and Brinkman, 2001). Because visceral
abdominal fat is known to be more metabolically active than
other fat tissues, altered adipocyte mitochondrial functioning
would affect central adipocytes more than peripheral adipo-
cytes. It is known that ATM is indispensable for mitochondrial
metabolism (Valentin-Vega et al., 2012). Based on these obser-
vations, one can speculate that loss of ATM would preferentially
affect peripheral adipocytes, in which mitochondrial functioning
is relatively low.
Our study revealed a previously uncharacterized function for
ATM as a regulator of key adipocyte transcription factors,
although its role in the DNA damage response pathway remains
to be determined. Based on our findings, agents such as the
PPARg ligand thiazolidione, which induces adipocytic differenti-
ation by bypassing the ATM pathway, may be good candidates
for treating glucose intolerance in A-T patients.
It is interesting that in Atm+/ mice, a high-fat diet, but not a
normal diet, induced glucose intolerance. Schneider et al. re-
ported that Atm+/ApoE/ mice fed a normal diet exhibited
glucose intolerance (Schneider et al., 2006). However, in our
study, Atm+/mice did not exhibit glucose intolerance, although
the genetic background of the Atm+/ApoE/ mice or the
increased serum lipid level generated by disabling the ApoE
gene may have affected the state of glucose tolerance. Never-
theless, our observations demonstrated the possibility of an
increased risk of metabolic syndrome in A-T carriers, which is
consistent with the epidemiological data supporting anll Reports 10, 957–967, February 17, 2015 ª2015 The Authors 963
Figure 7. Thiazolidione Treatment and Wild-Type Adipose Tissue Transplantation Rescues the Glucose-Intolerance Phenotype of Atm
Knockout Mice
(A) Rosiglitazone (Rosi) treatment restored the adipocyte differentiation capacity of Atm/ MEFs. Oil red O staining (left).
(B) Western blotting analysis. Differentiation was induced using DMSO or 1 mM rosiglitazone.
(C) Results of glucose tolerance tests ofAtm/mice treated withmetformin or pisoglitazone. These tests were performed before treatment (open diamond), after
metformin treatment (37.5 mg/kg, open triangle), and after pioglitazone treatment (30 mg/kg, closed square) for 21 consecutive days.
(D) Results of the insulin tolerance tests of mice treated as in (C).
(E) The serum adiponectin concentration of Atm/ mice before treatment (Pre) with pioglitazone (Pio) or metformin (Met). The mean values from three or four
independent experiments are shown.
(F) Results of the glucose tolerance tests performed after fat transplantation; Atm+/+ mice (closed diamond), Atm/ vehicle-transplanted mice (closed square),
Atm/ mice transplanted with Atm+/+ fat (open triangle), and Atm/ mice transplanted with Atm/ fat (gray circle).
(G) Results of the insulin tolerance tests of mice treated as in (G).
(H) The serum adiponectin concentrations in Atm+/+, Atm/ vehicle-transplanted, and Atm/ mice that received fat tissue transplants from Atm+/+ mice or
Atm/ mice are shown in the bar graph. The mean values from three or four independent experiments are shown.
The SEs are shown as error bars (*p < 0.05).increased risk for ischemic disease in A-T carriers (Su and Swift,
2000).
The ATM gene contains a number of SNPs, some of which
confer functional deficiencies. The frequency of these SNPs is964 Cell Reports 10, 957–967, February 17, 2015 ª2015 The Authorsestimated to be <5%. One report demonstrated that a genetic
locus responsible for type 2 diabetes is located on chromo-
some 11q, where ATM is also located (Palmer et al., 2006).
A genome-wide association study showed that one SNP,
rs11212617, at the ATM locus was associated with the suc-
cessful treatment of type 2 diabetes using metformin, suggest-
ing that ATM plays a role in the effect of metformin upstream
of AMPK (Zhou et al., 2011). Nucleotide variations or the inhi-
bition of ATM using KU-55933 alters the glycemic response to
metformin. However, the results of several studies do not sup-
port the hypothesis that ATM is involved in the activation of
AMPK through metformin (Florez et al., 2012; Woods et al.,
2012; Yee et al., 2012). Metformin activates the ATM-depen-
dent pathway and inhibits tumor growth and the sensitivity
to irradiation via an AMPK-dependent pathway (Storozhuk
et al., 2013; Vazquez-Martin et al., 2011). However, further
studies are required to elucidate the relationship between
the metformin-dependent glycemic response and ATM-depen-
dent glucose metabolism or the DNA damage response. It is
also known that individuals with type 2 diabetes have an
increased susceptibility to cancer. Together, these observa-
tions raised the question of whether ATM SNPs are associated
with the concomitant susceptibility to diabetes and malig-
nancy in certain individuals.
Thus, our study revealed a previously uncharacterized func-
tion for ATM in the regulation of key adipocyte transcription fac-
tors, although its role as a classical DNA damage responsemole-
cule remains to be determined. Understanding the functions of
ATM that are modulated by the DNA damage response in
glucose homeostasis may yield breakthroughs and reconsidera-
tion of the current paradigm for general diabetes research.
EXPERIMENTAL PROCEDURES
Animals
The generation of Atm-deficient mice (Atm/) was previously described
(Herzog et al., 1998). These mice have been backcrossed onto the C57BL/6
background for more than 15 generations. The mice were housed in a specific
pathogen-free barrier facility and weaned at 3 weeks of age to a standard
mouse chow that provided 6% of calories as fat. To produce the high-fat
diet group, mice were fed a diet that provided 42% of calories as fat. Animal
protocol 010018A was approved by the Animal Study Committee of Tokyo
Medical and Dental University.
Glucose Tolerance Test, Insulin Sensitivity Assay, Surgical
Implantation of Fat, and Pioglitazone and Metformin Treatment
Atm/ mice fed normal chow underwent glucose tolerance or insulin resis-
tance tests at 12 weeks of age. The mice were fasted for 12 hr, and then 10%
D-glucose (1 g/kg body weight) or human insulin (0.75 U/kg body weight;
Sigma-Aldrich) was administered via injection. Tail-vein blood (5 ml) was as-
sayed for glucose at 0, 30, 60, and 120 min after the injection using a glucose
meter (Medisense and Precision Xceed, Abbott Laboratories). Surgical implan-
tation of fat was performed as previously reported, with minor modifications
(Gavrilova et al., 2000). Intrascapular fat pads lacking brown adipose tissue
and inguinal fat pads were used. The homeostasis model assessment
(HOMA) indexwascalculatedaccording to the following formula: insulin (mU/ml)
3 glucose (mg/dl)/405) (Akagiri et al., 2008). Pioglitazone and metformin were
administered as previously described (Kita et al., 2012; Prieur et al., 2013).
Cells and Culture Conditions
3T3-L1 and 293T cells were maintained in DMEM supplemented with 10%
fetal calf serum, 2 mM glutamine, and 100 U/ml of penicillin and streptomycin
(P/S). Primary MEFs were cultured inmedium supplemented with 0.1 mM non-
essential amino acids, 55 mM 2-mercaptoethanol, and 100 U/ml P/S. The
Atm+/+ and Atm/MEF cell lines were maintained on an Arf-null background
as described previously (Kamijo et al., 1999). In terms of adipocyte differenti-Ceation, the Arf-null background did not affect competency, similar to the case of
the 3T3-L1 cell line, which lacks Arf expression.
In Vitro Adipocyte Differentiation Assay
The in vitro adipocyte differentiation assay was performed as previously
described (Tanaka et al., 1997). To induce adipocytic differentiation, the cells
were maintained at confluence for 2 days and were then switched to differen-
tiation medium (DMEM containing 5 mg/ml insulin, 1 mM dexamethasone, and
0.5 mM isobutyl methyl xanthine [Sigma-Aldrich]). The medium was replaced
every 2 days until the cells were analyzed. SVF analysis and in vitro differenti-
ation were performed as previously described (Rodeheffer et al., 2008).
Oil Red O Staining and Determination of Triglyceride Content
To stain adipocytes, the cells were washed twice with PBS and then incubated
with a filtered solution of 60% Oil red O (0.15 g/50 ml of 2-propanol) for 30 min
at 37C. The cells were washed briefly with 60% 2-propanol and then with wa-
ter before visualization. To measure their triglyceride content, the cells were
suspended in a buffer containing 150 mM NaCl, 10 mM Tris-HCl (pH 8.0),
0.1% Triton X-100, and protease inhibitors (Roche Diagnostics) and were son-
icated for 10 s on ice. The lysates were cleared by centrifugation, and the tri-
glyceride content was measured using a serum triglyceride determination kit
(Sigma).
Western Blotting and Immunoprecipitation
Western blotting was performed according to routine procedures. The immu-
noprecipitation experiments were performed as follows. First, the cells were
lysed using TGN buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1% NP-40,
0.5% Tween 20, and a phosphatase- and protease-inhibitor cocktail), and
then the antigens were precipitated using the antibodies described above after
precleaning the lysates using a control immunoglobulin G and protein A/G Se-
pharose beads (Santa Cruz Biotechnology). The precipitants were eluted by
boiling the beads in SDS buffer after six thorough washes using TGN buffer
containing 0.3 M LiCl. After SDS-PAGE, the blots were incubated with the
various antibodies and were visualized using TrueBlot technology
(eBioscience).
Immunofluorescence Microscopy
The cells were fixed using 4% paraformaldehyde at room temperature for
15 min, permeabilized using 0.5% Triton X-100/PBS at room temperature for
5 min, blocked using 10% FBS/PBS, and stained using primary antibodies
diluted in PBS containing 2% BSA overnight at 4C. The primary antibodies
were detected using an Alexa-488-conjugated anti-mouse secondary anti-
body (Invitrogen). The nuclei were stained using Vectashield containing DAPI
(Vector). Images were captured using an FV10i confocal microscope
(Olympus).
ChIP Assay
The ChIP assays were performed as previously described, with minor modifi-
cations (Berkovich et al., 2008). Protein-G Dynabeads were used instead of
protein-A agarose beads. The antibodies used for the ChIP assays included
C/EBPb (H7) from Santa Cruz Biotechnology and acetyl-histone H3 (06-599)
and H4 (06-866) from EMDMillipore. The primers used for the expression anal-
ysis of the C/EBPa promoter were previously reported (Tang et al., 2004).
Luciferase Assay
The C/EBPa-promoter luciferase-reporter plasmid was constructed as previ-
ously described (Tang et al., 1997). The luciferase activity was determined us-
ing the dual-luciferase reporter assay system (Promega).
Real-Time qPCR Assay
After RNA extraction with TRIzol reagent (Life Technologies), cDNAs were syn-
thesized using Superscript III (Life Technologies) and an oligo dT primer. PCR
amplification was performed using SYBR GreenER (Life Technologies), and
the amplified PCR product was monitored using a Bio-Rad MiniOption cycler.
Additional methods are provided in the Supplemental Experimental
Procedures.ll Reports 10, 957–967, February 17, 2015 ª2015 The Authors 965
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